Agilon Health (AGL Quick QuoteAGL - Free Report) reported $1.52 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 5.9%. EPS of $1.97 for the same period compares to -$6.75 a year ago.

The reported revenue represents a surprise of +4.43% over the Zacks Consensus Estimate of $1.45 billion. With the consensus EPS estimate being -$2.01, the EPS surprise was +198.01%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Avg. Medicare Advantage Members: 488,000 versus 438,150 estimated by two analysts on average.
• Revenues- Medical services: $1.52 billion versus $1.46 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
• Revenues- Other operating: $1.66 million compared to the $1.91 million average estimate based on two analysts. The reported number represents a change of -42.6% year over year.

View all Key Company Metrics for Agilon here>>>

Shares of Agilon have returned +5.3% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.